Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 2.977 -0.043 (-1.44%) Streaming Delayed Price Updated: 11:19 AM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Lexaria Bioscience Corp < Previous 1 2 3 4 5 6 7 8 9 ... 28 29 Next > CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study March 05, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study March 05, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 March 05, 2024 Via ACCESSWIRE Why Lexaria Bioscience (LEXX) Shares Are Moving February 15, 2024 Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering. Via Benzinga CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study March 04, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study March 04, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property 7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study March 04, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial March 01, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial March 01, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial March 01, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Wednesday's After-Market Session February 28, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session February 27, 2024 Via Benzinga Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering February 27, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering February 27, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering February 20, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering February 20, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D February 20, 2024 Via Investor Brand Network Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules February 16, 2024 Via ACCESSWIRE TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on $3.6M Registered Direct Offering February 15, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules February 15, 2024 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial February 14, 2024 Via Investor Brand Network Exposures Product Safety TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 Drug to Bloodstream February 12, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter February 12, 2024 Via Investor Brand Network 12 Health Care Stocks Moving In Friday's Intraday Session February 09, 2024 Via Benzinga Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap February 01, 2024 Via Investor Brand Network InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial January 30, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety Lexaria's Submits Investigational New Drug Application January 30, 2024 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) To Hit High Ground in Q2 and Q3 2024 with Animal and Human GLP-1 Study Programs January 29, 2024 Via Investor Brand Network TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Shares Company Update in Annual Shareholder Letter January 24, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Releases Annual Letter from the CEO January 24, 2024 Via ACCESSWIRE < Previous 1 2 3 4 5 6 7 8 9 ... 28 29 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.